Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report

Table 1 Case reports and retrospective series of lymphoepithelioma-like carcinoma management with programmed cell death protein 1/ programmed death-1 inhibition in combination with chemotherapy or targeted therapy

Case	Reference	EBV	PD-L1 expression	Previous treatment history	Treatment	Onset time	Best response	PFS (M)
1	Zhou et al[13]	NA	60%	1st-line chemotherapy	2nd-line nivolumab, 3rd-line nivolumab + anluotinib + gemcibabine	NA	SD	2, 4
2	Zhou et al[13]	NA	30%	NA	Nivolumab + gemcibabine	NA	SD	NA
3	Xie et al[7]	NA	15%	2nd-line chemotherapy	Camrelizumab + apatinib	NA	SD	7 +
4	Tang et al[11]	NA	10%	1st-line chemotherapy	2nd-line nivolumab, 3rd-line	Two cycles	PR	5
					Nivolumab + nedaplatin + paclitaxel	Four cycles	SD	NA
5	Zenget al (our case)	+	70%	Surgery	Sintilimab + paclitaxel + carboplation	Two cycles	PR	NA

EBV: Epstein–Barr virus; PD-L1: Programmed death-1; PFS: Progression-free survival; OS: Overall survival; PR: Partial response; SD: Stable disease; NA: Not available.